ATG-012 / Antengene - LARVOL DELTA

Synergistic effects of the combination of ERK1/2 with EGFR, KRASG12C, CDK4/6, and PD-L1 inhibition for cancer treatment (AACR 2023) - "This study tested the in vivo antitumor effects induced by the combination of ATG-017, with EGFR inhibitor (Osimertinib), KRASG12C inhibitor (ATG-012), CDK4/6 inhibitor (Abemaciclib) or PD-L1 inhibitor (Atezolizumab), in preclinical tumor models. The in vivo combinations of the drugs were tested in NCI-H1975, NCI-H358 (non-small cell lung cancer) or EL4 (T cell Lymphoma) CDX mouse models. Strong synergism has been observed for the combination of ATG-017 with EGFR, KRASG12C, CDK4/6, and PD-L1 inhibition, suggesting promising therapeutic strategies for cancer patients that warrants further investigation."

Hematological Malignancies • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • T Cell Non-Hodgkin Lymphoma • CD4 • CD8 • EGFR • KRAS • MAP2K1

Synergistic effects of the combination of Kras (G12C) with SHP2, ERK 1/2, mTORC1/2 or XPO1 inhibition for the treatment of Kras (G12C) mutated cancer (AACR 2022) - "This study tested the antitumor effects induced by the combination of ATG-012, a KRAS G12C inhibitor, with SHP2 inhibitor (ET0038), ERK 1/2 kinase inhibitor (ATG-017), mTORC1/2 kinase inhibitor (ATG-008) or XPO1 inhibitor (selinexor), in preclinical tumor models. The in vivo combinations of the drugs were tested in NCI-H358 (non-small cell lung cancer) and Mia-Paca-2 (pancreatic cancer) CDX mouse model. Strong in vivo synergism has been observed for the combination of a Kras (G12C) inhibitor (ATG-012) with a SHP2 inhibitor, ERK 1/2 inhibitor, mTORC1/2 inhibitor or XPO1 inhibitor, suggesting promising clinical therapeutic strategies for cancer patients carrying the KRAS G12C mutation."

IO biomarker • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting (PRNewswire) - "Antengene Corporation Limited...announced the publication of five posters that will be presented during the upcoming 2022 American Association for Cancer Research Annual Meeting (AACR 2022)....While ATG-012 monotherapy induced dose-dependent tumor growth inhibition at day 27,...the authors also found strong in vivo synergism in 2-agent combinations. In particular, ATG-012 and clinical stage ERK inhibitor (ATG-017) demonstrate strong in vitro and in vivo synergism, suggesting potential clinical application which may overcome the rapid resistance of KRAS inhibitors."

Preclinical • Oncology

Synergistic effect of the combination of ATG-017, an ERK1/2 inhibitor, and immune checkpoint inhibitor in preclinical cancer models (SITC 2021) - "Anti-PDL1 antibody (atezolizumab), the combination of ATG-012 or ATG-017 and atezolizumab, and the triple combination of atezolizumab, ATG-012 and ATG-017 were tested in a PD(L)1 blockade insensitive syngeneic lung cancer model,LL/2. More data from LL/2 and A20 model are being generated. Conclusions Synergism has been observed for the combination of checkpoint inhibition and ERK1/2 inhibition in vivo, suggesting promising therapeutic strategies for cancer patients that warrants further clinical investigation."

Checkpoint inhibition • IO biomarker • Preclinical • Hematological Malignancies • Lung Cancer • Lymphoma • Oncology • Solid Tumor • BRAF • CD8 • KRAS • PTPRC

Antengene Announces Financial Results for Full Year 2020 (PRNewswire) - "The company has submitted an IND application for the Phase I/II clinical study of ATG-016 in solid tumors in February 2021; The company is conducting IND enabling studies to support IND/CTA applications for ATG-101 and plans to submit the applications in 2021; The company is conducting preclinical studies to support IND/CTA applications for ATG-018 and plans to submit the applications in the beginning of 2022; The company is conducting preclinical studies to support IND/CTA applications for ATG-022...[& ATG-012] and plans to submit the applications in 2022."

IND • Oncology • Solid Tumor

Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange (PRNewswire) - "In addition, Antengene is working on early stage preclinical research and early drug development for several innovative-target drugs in the small molecule, monoclonal and bispecific antibody fields, including ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-018 (ATR inhibitor), ATG-022 (Claudin 18.2 monoclonal antibody) and ATG-012 (KRAS inhibitor), which are currently proceeding rapidly to IND stage."

Preclinical • Oncology